abstract |
The present invention provides a fusion protein as a hepatitis B therapeutic vaccine. The fusion protein comprises: (a) an antigen presenting cell (APC) binding domain or a CD91 receptor binding domain; (b) a protein transduction domain; and (c) an antigen comprising a hepatitis B virus X protein deletion mutant, which Lack of at least amino acids 21-50 of the X protein. The protein transduction domain is a fusion polypeptide, which includes a T cell sensitizing signal transduction peptide, a connecting peptide and a translocation peptide. The APC binding domain or CD91 receptor binding domain is located at the N-terminus of the fusion protein, and the antigen is located at the C-terminus of the protein conducting domain. |